Thank you for your understanding. Chinese biotechnology company JW Therapeutics is planning an initial public offering (IPO) in Hong Kong, joining a rush of pharmaceutical and biotech IPOs in the city.. JW Therapeutics, a joint venture between American biopharmaceutical company Juno Therapeutics and Chinese biotech WuXi AppTec, filed a draft prospectus with the Hong Kong … "Juno continues to make significant progress in developing new therapies with the potential to radically change the outlook for patients battling cancer," said Leerink Partners LLC acted as exclusive financial advisor in this transaction.Juno is a clinical stage company that brings together innovative technologies from three of the world's leading cancer centers – Fred Hutchinson Cancer Research Center, Memorial Sloan Kettering Cancer Center and Seattle Children's Research Institute – to advance a broad pipeline of potential curative immunotherapy treatments.

You can change your browser settings to disable these cookies, but it may affect your ability to access and use the site. JW Therapeutics, a Shanghai-based clinical-stage biopharmaceutical company, has completed of a US$100 million series B round financing co-led by CPE and Mirae Asset.CR-CP Life Science Fund and Oriza Holdings, as well as existing investors including Loyal Valley Capital, Temasek, Sequoia Capital China, ARCH Venture Partners, Juno Therapeutics, and WuXi AppTec also participated in the round.

These services are provided in Europe by Google Ireland Limited and elsewhere by Google LLC and affiliated Google Entities. All Rights Reserved.

Juno Therapeutics, Inc., a biotechnology company focused on bringing forward novel immunotherapies for cancer, today announced that it has closed its Series B round with $134M in new investment. (c)2011-2020 by Massinvestor, Inc. For contact info, please check out our This website uses cookies to ensure you get the best experience on our website. Juno Therapeutics is registered under the ticker NASDAQ:JUNO . If you miss a dose and it is within 6 hours of … JW Therapeutics, a Shanghai-based clinical-stage biopharmaceutical company, has completed of a US$100 million series B round financing co-led by CPE and Mirae Asset. A

Get exclusive offers to your inbox. We're here for you and your pet in 43 states. © 2020 China Money Network Limited.

Latham & Watkins provides first-class thought leadership across practices and industries, locally and globally. The company will use proceeds from the Series B round to continue advancing its chimeric antigen receptor (CAR) and T-cell receptor (TCR) pipeline, including CAR T-cell therapies directed against CD19 currently in phase 1/2 trials and solid tumor targets.

Juno's goal is to drive multiple product candidates in select hematologic and solid tumor cancers to FDA licensure.

$176M + See more Total Funding: $1.5B.

You can access and change your preferences at any time by clicking on the gear icon.

CR-CP Life Science Fund and Oriza Holdings, as well as existing investors including Loyal Valley Capital, Temasek, Sequoia Capital China, ARCH Venture Partners, Juno Therapeutics, and … In total Juno has raised $1.5B.

Disclaimer: The views, opinions, forecasts, and statements made by our hosts and guests are the personal views of those respective individuals and may or may not be either endorsed or accepted by China Money Network Limited or the companies with which these individuals are employed.

Juno Therapeutics is an American biopharmaceutical company founded in 2013 through a collaboration of the Fred Hutchinson Cancer Research Center, Memorial Sloan-Kettering Cancer Center and pediatrics partner Seattle Children's Research Institute.The company was launched with an initial investment of $120 million, with a remit to develop a pipeline of cancer immunotherapy drugs. JW Therapeutics is a clinical stage biopharmaceutical company founded by Seattle-based biopharmaceutical company Juno Therapeutics and Shanghai-based pharmaceutical and biotech contract research outsourcing provider WuXi AppTec Group in 2016 to focus on leading cell-based therapy technologies.The company has put into place a mature and stable process development system as well as the advancing cGMP manufacturing quality control system. Series A. Apr 2014.

We would like to use Google Analytics to analyse how visitors interact with our site so that we can continue to develop and improve it.
The investment was co-led by CPE and Mirae Asset, jointed by CR-CP Life Science Fund and Oriza Holdings, as well as existing investors including Loyal Valley Capital, Temasek, Sequoia Capital China, ARCH Venture Partners, Juno Therapeutics, a Bristol Myers Squibb company, and WuXi AppTec. All major prior investors participated as well. The company develops cell-based cancer immunotherapies based on its chimeric antigen receptor and T cell receptor technologies to genetically engineer T cells to recognize and kill cancer cells.

Juno Therapeutics Menu Juno Therapeutics These treatments have the potential to reduce longer-term toxicities associated with current chemotherapeutics.
It is focused on developing cellular immunotherapies for the treatment of cancer. Back in 2016, Juno Therapeutics (now owned by Celgene) and WuXi AppTec joined forces to create a new CAR-T biotech.